New drug combo offered to GIST patients with no other options
NCT ID NCT06948955
First seen Jun 26, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This expanded access program provides bezuclastinib, an investigational drug, combined with sunitinib for adults with advanced gastrointestinal stromal tumors (GIST) who cannot tolerate or have progressed on imatinib. The goal is to offer a potential treatment when no satisfactory alternatives exist. Participants must meet specific health criteria and commit to the program's assessments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bezuclastinib and sunitinib
- What this could lead to
- If this combination works, it could provide a new treatment option for people with advanced GIST who have run out of standard therapies.
- What could go wrong
- This is an expanded access program, not a formal trial, so data on effectiveness and safety is limited. The combination may not work for everyone and could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL NEOPLASMS, GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Foundation
AVAILABLECleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute (DFCI)
AVAILABLEBoston, Massachusetts, 02215, United States
-
Huntsman Cancer Institute, University of Utah
AVAILABLESalt Lake City, Utah, 84112, United States
-
Johns Hopkins University
AVAILABLEBaltimore, Maryland, 21287, United States
-
Karmanos Cancer Institute
AVAILABLEDetroit, Michigan, 48201, United States
-
MD Anderson Cancer Center
AVAILABLEHouston, Texas, 77030, United States
-
Mayo Clinic
AVAILABLEJacksonville, Florida, 32224, United States
-
Mayo Clinic
AVAILABLERochester, Minnesota, 55905, United States
-
Mayo Clinic Hospital
AVAILABLEPhoenix, Arizona, 85054, United States
-
Memorial Sloan Kettering Cancer Center
AVAILABLENew York, New York, 10065, United States
-
Northwest Medical Specialties
AVAILABLETacoma, Washington, 98405, United States
Contact Email: •••••@•••••
-
Northwestern Memorial Hospital
AVAILABLEChicago, Illinois, 60611, United States
Contact Email: •••••@•••••
-
Oregon Health and Sciences University
AVAILABLEPortland, Oregon, 97239, United States
-
Orlando Health
AVAILABLEOrlando, Florida, 32806, United States
-
Roswell Park Cancer Institute
AVAILABLEBuffalo, New York, 14263, United States
-
Shenandoah Oncology
AVAILABLEWinchester, Virginia, 22601, United States
-
Shenandoah Oncology
AVAILABLEWinchester, Virginia, 22601, United States
-
Smillow Cancer Hospital - Yale New Haven Health
AVAILABLENew Haven, Connecticut, 06510, United States
-
Taylor Cancer Research Center
AVAILABLEMaumee, Ohio, 43537, United States
-
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
AVAILABLEColumbus, Ohio, 43210, United States
-
The University of Chicago Medical Center
AVAILABLEChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
-
Thomas Jefferson University
AVAILABLEPhiladelphia, Pennsylvania, 19107, United States
-
UCLA Department of Medicine- Hematology/Oncology
AVAILABLELos Angeles, California, 90095, United States
-
UPMC Hillman Cancer Center
AVAILABLEPittsburgh, Pennsylvania, 15232, United States
-
USC/Norris Comprehensive Cancer Center
AVAILABLELos Angeles, California, 90033, United States
-
University of Colorado
AVAILABLEAurora, Colorado, 80045, United States